1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. global initiative for chronic obstructive lung disease (GOLD). 2011.

2. Salvi S.S., Barnes P.J. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009; 374: 733–743.

3. Bai P., Sun Y., Jin J. et al. Disturbance of the OPG / RANK / RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis. Respir. Res. 2011; 12: 157.

4. Tanni S.E., Pelegrino N.R., Angeleli A.Y. et al. Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. J. Inflamm. 2010; 7: 29.

5. Lim S.C., Ju J.Y., Chi S.Y. et al. Apoptosis of T lymphocytes isolated from peripheral blood of patients with acute exacerbation of chronic obstructive pulmonary disease. Yonsei Med. J. 2011; 52 (4): 581–587.

6. Dickens J.A., Miller B.E., Edwards L.D. et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir. Res. 2011; 12: 146.

7. Schols A.M., Buurman W.A., Staal van den Brekel A.J. et al. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51 (8): 819–824.

8. Aaron S.D., Vandemheen K.L., Ramsay T. et al. Multi analyte profiling and variability of inflammatory markers in blood and induced sputum in patients with stable COPD. Respir. Res. 2010; 11: 41.

9. Garcia7Rio F., Miravitlles M., Soriano J.B. et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study. Respir. Res. 2010; 11: 63.

10. Serapinas D., Narbekovas A., Juskevicius J. et al. Systemic inflammation in COPD in relation to smoking status. Multidiscip. Respir. Med. 2011; 6 (4): 214–219.

11. de Jong J.W., van der Belt7Gritter B., Koeter G.H. et al. Peripheral blood lymphocyte cell subsets in subjects with chronic obstructive pulmonary disease: association with smoking, IgE and lung function. Respir. Med. 1997; 91 (2): 67–76.

12. World Health Organization. Guidelines for controlling and monitoring the tobacco epidemic. Genewa: WHO; 2008.

13. Jones P.W., Harding G., Berry P. et al. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009; 34 (3): 648–654.

14. Anthonisen N.R., Manfreda J., Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obsructive pulmonary disease. Ann. Intern. Med. 1987; 106 (2): 196–204.

15. Wanger J., Clausen J.L., Coates A. et al. Standartisation of the measurement of lung volumes. Eur. Respir. J. 2005; 26 (3): 511–522.

16. Murphy P.M. Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin. Hematol. 1997; 34 (4): 311–318.

17. Rossi G.A. COPD patients or "healthy smokers": is IL-8 synthesis and release the borderline? Respiration 2003; 70 (5): 457–459.

18. Barnes P.J. Mediators of chronic obstructive pulmonary disease. Pharmacol. Rev. 2004; 56 (4): 515–548.

19. Жестков А.В., Косарев В.В., Бабанов С.А. и др. Клинико-иммунологические особенности профессионального бронхита. Пульмонология 2008; 4: 31–35.

20. Petrescu F., Voican S.C., Silosi I. Tumor necrosis factor-α serum levels in healthy smokers and nonsmokers. Int. J. Chron. Obsruct. Pulm. Dis. 2010; 5: 217–222.

21. Shirai T., Suda T., Inui N. et al. Correlation between peripheral blood T-cell profiles and clinical and inflammatory parameters in stable COPD. Allergol. Int. 2010; 59 (1): 75–82.

22. Chung K.F. Cytokines in chronic obstructive pulmonary disease. Eur. Respir. J. 2001; 18 (34): 50s–59s.

23. Torvinen M., Campwala H., Kilty I. The role of IFN-γ in regulation of IFN-γ-inducible protein 10 (IP-10) expression in lung epithelial cell and peripheral blood mononuclear cell co-cultures. Respir. Res. 2007; 8: 80.